BioSpace News Archive

22nd Century Group, Inc., a leading plant-based biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and hemp/cannabis research, announced that the Company will participate in the following virtual investor conferences in May and June 2021

Veriskin, Inc., a start-up medical device company, has invented and is developing novel technology for skin cancer diagnostics and screening. Veriskin has received FDA Breakthrough Device Designation for its TruScore device in July, 2020. Development of this innovative technology is being supported by grant funding from the National Cancer Institute and seed-round capital from private investors.

Scopus BioPharma Inc. (Nasdaq: “SCPS”) today announced the approval of an investigational new drug application (“IND”) by the United States Food and Drug Administration (“FDA”) for CpG-STAT3siRNA, the company’s distinctive immuno-oncology RNA therapy for the treatment of multiple cancers.

ATI Physical Therapy (ATI), one of the nation’s largest providers of physical therapy services, today announced that Labeed Diab , CEO, and Joe Jordan , CFO, will participate in the following upcoming investor conferences:

Confluent Medical Technologies Announces Expansion of the Confluent Costa Rica Manufacturing Location To Meet Growing Demand in Nitinol Processing & Specialized Catheters

Ziopharm Oncology, Inc., a clinical-stage cellular therapy company focused on hematologic and solid tumor cancers, announced that Company management will participate in two upcoming investor conferences

Biostage, Inc. (OTCQB: BSTG) (“Biostage” or the “Company”), a bioengineering company developing next-generation esophageal implants based its novel Cellframe™ and Cellspan™ technology, today announced its financial results for the three months ended March 31, 2021 .

Electromed was selected for the honor from the 2021 Quality Leadership Top 100 Company survey published annually by the magazine.

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced a proposed underwritten public offering in which it intends to offer and sell shares of its common stock.

Quidel Corporation (NASDAQ: QDEL) (“Quidel”) , a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that its Sofia® SARS Antigen FIA is the first rapid antigen test to receive authorization from Health Canada for serial testing for the detection of active coronavirus infection in both symptomatic and asymptomatic populations.